Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Concern With Potential Rise in Super Potent Cannabis Concentrates

By University of Queensland | July 24, 2017

Concern over the rise in use of super potent cannabis. Source: University of Queensland

University of Queensland researchers are concerned the recent legalisation of medicinal cannabis in Australia may give rise to super-potent cannabis concentrates with associated harmful effects.

UQ Centre for Youth Substance Abuse Research’s Dr Gary Chan, who led the butane hash oil study, said a significant proportion of cannabis users used the concentrate.

“Butane hash oil is a cannabis concentrate that is over 10 times more potent than herbal cannabis,” Dr Chan said.

“Although users were more likely to report medical use, the use of butane hash oil was associated with high levels of depression, anxiety disorder and other illicit substance use.

“These results were consistent globally.”

The research was based on data from the Global Drug Survey, the world’s largest drug survey that collects data about drug users.

The tetrahydrocannabinol (THC) content of butane hash oil can be as high as 80 per cent. In comparison, the THC content in herbal cannabis is approximately 9-15 per cent, depending on the method of cultivation.

Butane hash oil is produced by solvent extraction (maceration, infusion or percolation) of marijuana or hashish.

After filtering and evaporating the solvent, a sticky resinous dark liquid with a strong herbal odour remains.

Dr Chan said there had been a rise of butane hash oil use in the United States, and considered it to be an unexpected by-product of cannabis legalisation.

“The production and promotion of hyper-potent cannabis concentrates with 70 to 80 per cent THC now account for 20 per cent of the markets in Washington and Colorado, and use of these hyper-potent products seem to be gaining popularity in Canada,” he said.

“Given that Australia has recently legalised medical cannabis use, surveillance needs to take note of any rise in the use of concentrates because it can be produced with relatively simple equipment that is easily accessible.

“However, at this stage there is no evidence for medical use of butane hash oil for any health condition.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50